178 related articles for article (PubMed ID: 35418130)
1. Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
Wathikthinnakon M; Luangwattananun P; Sawasdee N; Chiawpanit C; Lee VS; Nimmanpipug P; Tragoolpua Y; Rotarayanont S; Sangsuwannukul T; Phanthaphol N; Wutti-In Y; Somboonpatarakun C; Chieochansin T; Junking M; Sujjitjoon J; Yenchitsomanus PT; Panya A
Sci Rep; 2022 Apr; 12(1):6154. PubMed ID: 35418130
[TBL] [Abstract][Full Text] [Related]
2. A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma.
Li B; Wang S; Shan B; Li B; Li F
Mol Immunol; 2023 Nov; 163():20-27. PubMed ID: 37722180
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173
[TBL] [Abstract][Full Text] [Related]
8. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
9. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in extrahepatic cholangiocarcinoma.
Walter D; Herrmann E; Schnitzbauer AA; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
Histopathology; 2017 Sep; 71(3):383-392. PubMed ID: 28419539
[TBL] [Abstract][Full Text] [Related]
11. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells.
Sawasdee N; Thepmalee C; Sujjitjoon J; Yongpitakwattana P; Junking M; Poungvarin N; Yenchitsomanus PT; Panya A
Int Immunopharmacol; 2020 Jan; 78():106006. PubMed ID: 31780372
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
[TBL] [Abstract][Full Text] [Related]
14. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
Sangsuwannukul T; Supimon K; Chieochansin T; Choomee K; Sujjitjoon J; Junking M; Yenchitsomanus PT
PLoS One; 2022; 17(3):e0265773. PubMed ID: 35312724
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma.
Mocan LP; Craciun R; Grapa C; Melincovici CS; Rusu I; Al Hajjar N; Sparchez Z; Leucuta D; Ilies M; Sparchez M; Mocan T; Mihu CM
Cancer Immunol Immunother; 2023 Apr; 72(4):1003-1014. PubMed ID: 36251029
[TBL] [Abstract][Full Text] [Related]
17. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
[TBL] [Abstract][Full Text] [Related]
18. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
19. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
20. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]